Koichi Node
10 Papers
Koichi Node is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has co-authored 4 publications.
Chat about Author
Papers
Long-term observation of estimated fluid volume reduction after the initiation of ipragliflozin in patients with type 2 diabetes mellitus: a sub-analysis from a randomized controlled trial (PROTECT)
Atsushi Tanaka,Takumi Imai,Shigeru Toyoda,Kazuhiro Sugimoto,Ruka Yoshida,Machi Furuta,Koichi Node +6 more
TL;DR: In this paper , the authors examined the long-term effect of the SGLT2 inhibitor ipragliflozin on the estimated fluid volume parameters in patients with type 2 diabetes mellitus (T2DM).
Effect of Ipragliflozin on Endothelial Dysfunction in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Randomized Clinical Trial (PROCEED).
Atsushi Tanaka,Yosuke Okada,Keiichi Torimoto,Nozomu Kamei,Hiroyuki Hirai,Kazuhiro Sugimoto,Hiroki Teragawa,Isao Taguchi,Tatsuya Maruhashi,Satomi Sonoda,Akira Kurozumi,Saori Inagaki,Chikage Oshita,Itaru Hisauchi,Kanae Takahashi,Yukihito Higashi,Michio Shimabukuro,Koichi Node +17 more
2
Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR)
Atsushi Tanaka,Hirotaka Shibata,Takumi Imai,Hisako Yoshida,Motoaki Miyazono,Naohiko Takahashi,Daiju Fukuda,Yosuke Okada,Hiroki Teragawa,Satoru Suwa,Keisuke Kida,Masao Moroi,Isao Taguchi,Shigeru Toyoda,Michio Shimabukuro,Kengo Tanabe,Kenichi Tanaka,Masaomi Nangaku,Koichi Node +18 more
TL;DR: FIVE-STAR is the first trial evaluating the therapeutic impact of finerenone on vascular stiffness and relevant cardiorenal biomarkers in patients with T2D and CKD and will provide mechanistic insights on the clinical benefits of finerenone based on recent cardiovascular and renal outcome trials.
2
Erythropoiesis and estimated fluid volume regulation following initiation of ipragliflozin treatment in patients with type 2 diabetes mellitus and chronic kidney disease: A post-hoc analysis of the PROCEED trial.
Tatsuya Maruhashi,Atsushi Tanaka,Kanae Takahashi,Yukihito Higashi,Koichi Node +4 more
TL;DR: Erythropoiesis was enhanced and estimated fluid volumes were reduced by ipragliflozin in patients with T2DM and CKD, a post-hoc analysis of the PROCEED trial.
1
Effects of finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomised placebo-controlled mechanistic trial (FIVE-STAR)
Atsushi Tanaka,Muthiah Vaduganathan,Takumi Imai,Yosuke Okada,Satomi Sonoda,Keiichi Torimoto,Satoru Suwa,Hiroki Teragawa,Motoaki Miyazono,Makoto Fukuda,Keisuke Yonezu,Naohiko Takahashi,Yuichi Yoshida,Kenichi Tanaka,Michio Shimabukuro,Yuki Hotta,Masao Moroi,Hiroki Niikura,Keisuke Kida,Kenichi Yokota,Daiju Fukuda,Kengo Tanabe,Yu Horiuchi,Shigeru Toyoda,Isao Taguchi,Hisako Yoshida,Toru Miyoshi,M. Nangaku,Hirotaka Shibata,Koichi Node +29 more
TL;DR: This mechanistic trial found that finerenone therapy in patients with type 2 diabetes and chronic kidney disease reduced albuminuria by 29% at 24 weeks, but did not significantly affect vascular stiffness or circulating protein levels, suggesting a potential mechanism of lowering intraglomerular pressure.